Home / Business and Economy / Cancer Drug Firm Aktis Oncology Raises $318M in IPO

Cancer Drug Firm Aktis Oncology Raises $318M in IPO

9 Jan

Summary

Aktis Oncology priced its initial public offering at $18 per share.
The company successfully raised approximately $318 million in the IPO.
Aktis Oncology targets a valuation of up to $945.4 million.

Cancer Drug Firm Aktis Oncology Raises $318M in IPO

Cancer drug developer Aktis Oncology has successfully priced its U.S. initial public offering (IPO), raising substantial capital for its operations. The company announced on Thursday that its upsized offering was priced at $18 per share, generating approximately $318 million.

This significant funding infusion positions Aktis Oncology for future growth and development of its innovative cancer therapies. The IPO targets a valuation of up to $945.4 million, reflecting investor confidence in the company's potential.

The successful completion of the IPO provides Aktis Oncology with the necessary resources to advance its pipeline and pursue its mission of developing groundbreaking treatments for cancer patients.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.